Dacarbazine

Generic Name
Dacarbazine
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C6H10N6O
CAS Number
4342-03-4
Unique Ingredient Identifier
7GR28W0FJI
Background

An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.

Indication

For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.

Associated Conditions
Advanced Pancreatic Neuroendocrine Tumors (pNET), Advanced Soft Tissue Sarcoma, Hodgkin's Lymphoma, Metastatic Melanoma, Pheochromocytoma, Advanced Medullary thyroid cancer
Associated Therapies
-
Clinical Trials
Related News

Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma

Phase 2
Completed
Conditions
Melanoma
Interventions
Drug: Ipilimumab
Drug: Dacarbazine
First Posted Date
2012-09-07
Last Posted Date
2015-06-11
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
21
Registration Number
NCT01681212
Locations
🇯🇵

Local Institution, Chuo-shi, Yamanashi, Japan

Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma

First Posted Date
2012-04-03
Last Posted Date
2018-10-29
Lead Sponsor
University of Cologne
Target Recruit Count
100
Registration Number
NCT01569204
Locations
🇩🇪

1st Dept. of Medicine, Cologne University Hospital, Cologne, Germany

A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma

Phase 2
Completed
Conditions
Metastatic Uveal Melanoma
Interventions
Drug: Sunitinib
Drug: Dacarbazine
First Posted Date
2012-03-12
Last Posted Date
2019-10-29
Lead Sponsor
The Clatterbridge Cancer Centre NHS Foundation Trust
Target Recruit Count
124
Registration Number
NCT01551459
Locations
🇬🇧

Clatterbridge Centre for Oncology NHS Foundation Trust, Wirral, United Kingdom

Metronomic Therapy in Patients With Metastatic Melanoma

First Posted Date
2012-03-02
Last Posted Date
2019-01-15
Lead Sponsor
Dartmouth-Hitchcock Medical Center
Target Recruit Count
7
Registration Number
NCT01542255
Locations
🇺🇸

Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

First Posted Date
2011-11-22
Last Posted Date
2020-02-17
Lead Sponsor
Northwestern University
Target Recruit Count
48
Registration Number
NCT01476410
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

🇺🇸

Stanford University Medical Center, Stanford, California, United States

🇺🇸

Memorial Sloan- Kettering Cancer Center, New York, New York, United States

and more 4 locations

Prospective Study on HIV-related Hodgkin Lymphoma

First Posted Date
2011-11-09
Last Posted Date
2011-11-09
Lead Sponsor
Harlachinger Krebshilfe e.V.
Target Recruit Count
130
Registration Number
NCT01468740
Locations
🇩🇪

Infektionsmedizinisches Zentrum Hamburg, Hamburg, Germany

🇩🇪

Vivantes Auguste Victoria Klinikum, Berlin, Germany

🇩🇪

Ärzteforum Seestrasse, Berlin, Germany

and more 5 locations

Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease

First Posted Date
2011-07-28
Last Posted Date
2013-02-01
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
35
Registration Number
NCT01404936
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

First Posted Date
2011-07-11
Last Posted Date
2023-06-29
Lead Sponsor
ECOG-ACRIN Cancer Research Group
Target Recruit Count
6
Registration Number
NCT01390584
Locations
🇺🇸

Stanford Cancer Center, Stanford, California, United States

🇺🇸

McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center, Reading, Pennsylvania, United States

Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma

First Posted Date
2011-05-25
Last Posted Date
2023-04-11
Lead Sponsor
National Cancer Institute, Naples
Target Recruit Count
269
Registration Number
NCT01359956

A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

First Posted Date
2011-04-28
Last Posted Date
2016-08-26
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
579
Registration Number
NCT01343277
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy